Poolbeg Pharma Regulatory News (POLB)

Poolbeg Pharma plc

Two posters with POLB 001 preclinical data presented at the European Hematology Association Congress

Posters highlight POLB 001's potential in CRS prevention and ability to enhance AML treatment in elderly patients, potentially expanding into a new indication 

· First poster shows that POLB 001 decreased key CRS-associated cytokines and did not impair bispecific antibody-induced tumour cell death in a series of preclinical investigations

· Second poster demonstrates the potential for POLB 001 to improve outcomes for elderly AML patients, positioning AML as a potential new indication for POLB 001

11 June 2026 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces new research on two posters, by Poolbeg and The University of Manchester respectively, are being presented at the European Hematology Association Congress ("EHA"), in Stockholm, Sweden which runs from Thursday 11 June until Sunday 14 June 2026.

1. Poster on the in vitro and in vivo effects of POLB 001 on cytokine release syndrome ("CRS") and T cell phenotype and function

This poster, presented by Poolbeg, details the in vitro and in vivo effects of POLB 001 on cytokine release syndrome ("CRS") and T cell phenotype and function. The in vitro studies utilised primary human blood samples co-cultured with a human tumour cell line and two commercially available bispecific antibodies ("BsAb"). The in vivo study assessed the impact of prophylactic POLB 001 in a humanised tumour-bearing mouse model of BsAb induced CRS.

Key highlights:

Title: POLB 001, an oral p38 MAPK Inhibitor for the Prevention of Cytokine Release Syndrome

Poster Session: Poster Session 2, Hall A

Session Date and Time: Saturday, 13 June 2026, 18:45 - 19:45 CEST

Authors: L. Tremble, P. Maguire, M. Arora, J. Froggatt, J. Skillington, B. Buckley, R. Popat, E. Searle.

Abstract Code: PS1845

2. Poster on the potential for POLB 001 to improve outcomes for elderly AML patients

This poster, presented by The University of Manchester, highlights the potential for POLB 001 to improve outcomes for elderly Acute Myeloid Leukaemia ("AML") patients in combination with Azacitidine ("AZA"). The key findings from this in vivo study provide early preclinical evidence that POLB 001 may enhance the efficacy of azacitidine in aged mouse models of AML. Azacitidine is a first-line treatment offered to patients with AML.

Poster 2 Presentation Details:

Title: Targeting inflammation via p38MAPK inhibition to improve azacitidine efficacy in aged AML

Poster Session: Poster Session 2, Hall A

Session Date and Time: Saturday 13 June 2026, 18:45 - 19:45 CEST

Authors: A. Vitlic, S. Menegatti, W. Yang, Z. Jia, S. Nickaria, L. Tremble, P. Maguire, S. Valletta

Abstract Code: PS1565

Liam Tremble, Principal Scientist of Poolbeg Pharma, said: " This novel data in CRS reinforces the potential of POLB 001 to address one of the most significant challenges associated with cancer immunotherapy. We believe POLB 001 could play an important role in improving both the safety and accessibility of these transformative therapies, and we look forward to sharing interim data from the TOPICAL trial in multiple myeloma patients later this summer. The results in preclinical models of AML generated and being presented at EHA by the University are highly encouraging and point to the potential clinical utility of POLB 001 beyond CRS. AML is a disease of the elderly and current treatment strategies are poorly suited for a frail patient population"

Enquiries

About Poolbeg Pharma plc

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Poolbeg is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's largest markets. With multiple near-term clinical value inflection points, and an experienced team with a proven track record, Poolbeg is focussed on partnering its high value programmes that are targeting large markets and addressing critical unmet medical needs. 

Stay updated: Website | Sign up for RNS alerts | Presentation | X | LinkedIn

Forward-Looking Statements

This announcement may contain forward-looking statements and the words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Poolbeg's present and future business strategies and the environment in which Poolbeg expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond Poolbeg's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Poolbeg's ability to obtain financing, changes in the political, social and regulatory framework in which Poolbeg operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information.